Geode Capital Management
FDMT icon

Geode Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Geode Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15M Buy
1,128,466
+63,121
+6% +$615K ﹤0.01% 2315
2026
Q1 		$9.92M Buy
1,065,345
+53,320
+5% +$464K ﹤0.01% 2386
2025
Q4 		$7.59M Buy
1,012,025
+98,506
+11% +$999K ﹤0.01% 2541
2025
Q3 		$7.94M Sell
913,519
-5,014
-0.5% -$30K ﹤0.01% 2547
2025
Q2 		$3.41M Sell
918,533
-44,736
-5% -$157K ﹤0.01% 2926
2025
Q1 		$3.11M Sell
963,269
-48,893
-5% -$230K ﹤0.01% 2869
2024
Q4 		$5.64M Sell
1,012,162
-24,383
-2% -$191K ﹤0.01% 2682
2024
Q3 		$11.2M Sell
1,036,545
-24,346
-2% -$404K ﹤0.01% 2312
2024
Q2 		$22.3M Buy
1,060,891
+188,228
+22% +$4.72M ﹤0.01% 1875
2024
Q1 		$27.8M Buy
872,663
+94,501
+12% +$2.41M ﹤0.01% 1727
2023
Q4 		$15.8M Buy
778,162
+36,497
+5% +$480K ﹤0.01% 2054
2023
Q3 		$9.44M Buy
741,665
+51,888
+8% +$868K ﹤0.01% 2303
2023
Q2 		$12.5M Buy
689,777
+111,855
+19% +$2.06M ﹤0.01% 2152
2023
Q1 		$9.93M Buy
577,922
+16,185
+3% +$315K ﹤0.01% 2259
2022
Q4 		$12.5M Buy
561,737
+32,801
+6% +$507K ﹤0.01% 2103
2022
Q3 		$4.25M Buy
528,936
+36,111
+7% +$327K ﹤0.01% 2757
2022
Q2 		$3.44M Buy
492,825
+14,202
+3% +$138K ﹤0.01% 2900
2022
Q1 		$7.24M Sell
478,623
-3,814
-0.8% -$59.9K ﹤0.01% 2575
2021
Q4 		$10.6M Buy
482,437
+140,219
+41% +$3.44M ﹤0.01% 2406
2021
Q3 		$9.23M Buy
342,218
+174,784
+104% +$4.98M ﹤0.01% 2505
2021
Q2 		$4.03M Buy
167,434
+21,136
+14% +$647K ﹤0.01% 3030
2021
Q1 		$6.35M Buy
146,298
+133,518
+1,045% +$5.91M ﹤0.01% 2663
2020
Q4 		$529K Buy
+12,780
New +$528K ﹤0.01% 3573

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Geode Capital Management's FDMT Position: Q2 2026 in Review

Geode Capital Management increased its 4D Molecular Therapeutics (FDMT) stake by 5.9% in Q2 2026, buying an estimated $615K and bringing the position to 1,128,466 shares worth $15M. The position accounts for ﹤0.01% of the portfolio, ranked #2315.

Geode Capital Management first reported a position in FDMT in Q4 2020 and has held it in 23 quarters since. The position peaked at $27.8M in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Geode Capital Management held 1,128,466 shares of 4D Molecular Therapeutics worth $15M as of Q2 2026.
  • Geode Capital Management bought 63,121 4D Molecular Therapeutics shares in Q2 2026, an estimated $615K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2315 holding.
  • Geode Capital Management first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Geode Capital Management's 4D Molecular Therapeutics position peaked at $27.8M in Q1 2024.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.